Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis
- 678 Downloads
Intravenous tissue plasminogen activator (tPA) thrombolysis remains the only proven pharmacological treatment for acute ischemic stroke . A common clinical scenario is where a patient with atrial fibrillation (AF) on therapeutic anticoagulation presents with an acute ischemic stroke but thrombolysis is absolutely contraindicated due to hemorrhagic risk.
KeywordsDabigatran Acute Ischemic Stroke Perfusion Compute Tomography Hemispheric Stroke Hemispheric Infarct
Compliance with ethical standards
Consent for case reports
Written consents were obtained by patient and families.
Conflicts of interest
The authors declare that they have no conflict of interest.
- 1.Demaerschalk BM, Kleindorer DO, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy El Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE, American Heart Association Stroke Council and Council on Epidemiology and Prevention (2016) Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke. Stroke 47:581–641CrossRefPubMedGoogle Scholar